Skip to content
The Nexus
DossierENTITY

Teva Pharmaceuticals

Coverage of Teva Pharmaceuticals in the Nexus archive.

Earliest in view: May 28 · 18:48 UTCMost recent: Jul 29 · 23:55 UTC
Co-mentioned in this coverage
Richard Francisperson1Bloombergorganization1Medicaretopic1NYSEorganization1Q2 Earningstopic1Jeremy Levinperson1Ovid Therapeuticsorganization1Biotech in the Balance: Saving a Strategic Industry in an Age of Distrusttopic1regulatory upheavaltopic1pharmaceutical companiesorganization1
Recent coverage
  • BUSINESSJul 29 · 23:55 UTCBLOOMBERG
    Teva CEO on Drug Pipeline, Direct Listing on NYSE

    Teva Pharmaceuticals CEO Richard Francis discussed the company's positive Q2 earnings, the impact of changing Medicare rules on patients, and the new direct listing on the NYSE with Bloomberg reporter Romaine Bostick.

  • HEALTHMay 28 · 18:48 UTCSTAT NEWS
    STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk

    Jeremy Levin, founder of Ovid Therapeutics and former CEO of Teva Pharmaceuticals, argues in his book that political upheaval, weakening institutions, and short-term investing threaten the biotech industry's future despite scientific advancements. He advocates for federal policy changes to support biotech investment and for pharmaceutical companies to address regulatory challenges.